Although INGAP-PP treatment in humans did not yield definitive conclusions, it did show improvement in some parameters assessed, such as arginine-stimulated C-peptide secretion in the T1D trial and HbA1C levels in the T2D trial (22). Here, REG3A is linked to type 2 diabetes mellitus.